Advertisement

Disorders of Lipid and Lipoprotein Metabolism

  • DeWitt S. Goodman

Abstract

It is the aim of this chapter to review the major advances that occurred during 1975 with regard to our knowledge about the metabolism of the major plasma lipids and lipoproteins, and about clinical abnormalities in lipid transport, with particular emphasis on the hyperlipidemias. In addition, some recent major developments that occurred before 1975 will be reviewed briefly in order to provide important background information. The well-established association between the presence of hyperlipidemia and an increased risk of the development of coronary heart disease (Kannel et al., 1961, 1971; Carlson and Böttiger, 1972) has served to stimulate both biochemists and clinicians to focus considerable research efforts on this area.

Keywords

Familial Hypercholesterolemia Lipoprotein Metabolism Familial Hypercholesterolemia Cholesterol Acyltransferase Portacaval Shunt 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ahrens, E. H., Jr., 1974, Homozygous hypercholesteremia and the portacaval shunt: The need for a concerted attack by surgeons and clinical researchers, Lancet 2: 449–451.PubMedCrossRefGoogle Scholar
  2. Bagdade, J. D., Porte, D., Jr., and Bierman, E. L., 1968, Hypertriglyceridemia: A metabolic consequence of chronic renal failure, N. Engl. J. Med. 279: 181–185.CrossRefGoogle Scholar
  3. Baker, H. N., Gotto, A. M., Jr., and Jackson, R. L., 1975, The primary structure of human plasma high density apolipoprotein glutamine I (ApoA-I). II. The amino acid sequence and alignment of cyanogen bromide fragments IV, III, and I, J. Biol. Chem. 250: 2725–2738.PubMedGoogle Scholar
  4. Beaumont, J. L., Carlson, L. A., Cooper, G. R., Fejfar, Z., Fredrickson, D. S., and Strasser, T., 1970, Classification of hyperlipidemias and hyperlipoproteinemias, Bull. W. H. O. 43: 891–915.PubMedGoogle Scholar
  5. Beaumont, J. E., Luke, R. G., Galla, J. H., Rees, E. D., and Siegel, R. R., 1975, Normal serum-lipids in renal-transplant patients, Lancet 1: 599–601.PubMedCrossRefGoogle Scholar
  6. Bilheimer, D. W., Goldstein, J. L., Grundy, S. M., and Brown, M. S., 1975, Reduction in cholesterol and low density lipoprotein synthesis after portacaval shunt surgery in a patient with homozygous familial hypercholesterolemia, J. Clin. Invest. 56: 1420–1430.PubMedCrossRefGoogle Scholar
  7. Blacket, R. B., Leelarthaepin, B., Woodhill, J. M., and Palmer, A. J., 1975, Type- IV hyperlipidemia and weight-gain after maturity, Lancet 2: 517–520.PubMedCrossRefGoogle Scholar
  8. Breslow, J. L., Spaulding, D. R., Lux, S. E., Levy, R. I., and Lees, R. S.,. 1975, Homozygous familial hypercholesterolemia: A possible biochemical explanation of clinical heterogeneity, N. Engl. J. Med. 293: 900–903.PubMedCrossRefGoogle Scholar
  9. Brewer, H. B., Jr., Shulman, R., Herbert, P., Ronan, R., and Wehrly, K., 1974, The complete amino acid sequence of alanine apolipoprotein (apoC-III), an apolipoprotein from human plasma very low density lipoproteins, J. Biol. Chem. 249: 4975–4984.PubMedGoogle Scholar
  10. Brown, M. S., and Goldstein, J. L., 1974, Suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and inhibition of growth of human fibroblasts by 7-ketocholesterol, J. Biol. Chem. 249: 7306–7314.PubMedGoogle Scholar
  11. Brown, M. S., and Goldstein, J. L., 1975, Regulation of the activity of the low density lipoprotein receptor in human fibroblasts, Cell 6: 307–316.PubMedCrossRefGoogle Scholar
  12. Brown, M. S., Brannan, P. G., Bohmfalk, H. A., Brunschede, G. Y., Dana, S. E., Helgeson, J., and Goldstein, J. L., 1975a, Use of mutant fibroblasts in the analysis of the regulation of cholesterol metabolism in human cells, J. Cell. Physiol. 85: 425–436.PubMedCrossRefGoogle Scholar
  13. Brown, M. S., Faust, J. R., and Goldstein, J. L., 1975b, Role of the low density lipoprotein receptor in regulating the content of free and esterified cholesterol in human fibroblasts, J. Clin. Invest. 55: 783–793.PubMedCrossRefGoogle Scholar
  14. Brunzell, J. D., Hazzard, W. R., Motulsky, A. G., and Bierman, E. L., 1975, Evidence for diabetes mellitus and genetic forms of hypertriglyceridemia as independent entities, Metabolism 24: 1115.PubMedCrossRefGoogle Scholar
  15. Carlson, L. A., and Böttiger, L. E., 1972, Ischemic heart disease in relation to fasting values of plasma triglycerides and cholesterol, Lancet 1: 865–868.PubMedCrossRefGoogle Scholar
  16. Carlson, L. A., Ekelund, L. G., and Olsson, A. G., 1975, Frequency of ischemic exercise E.C.G. changes in symptom-free men with various forms of primary hyperlipemia, Lancet 2: 1–3.PubMedCrossRefGoogle Scholar
  17. Casaretto, A., Goldsmith, R., Marchioro, T. L., and Bagdade, J. D., 1974, Hyperlipidemia after successful renal transplantation, Lancet 1: 481–484.PubMedCrossRefGoogle Scholar
  18. Connor, W. E., Stone, D. B., and Hodges, R. E., 1964, The interrelated effects of dietary cholesterol and fat upon human serum lipid levels, J. Clin. Invest. 43: 1691–1696.PubMedCrossRefGoogle Scholar
  19. Cooper, J., Geizerova, H., and Oliver, M. F., 1975, Clofibrate and gallstones, Lancet 1: 1083.PubMedCrossRefGoogle Scholar
  20. The Coronary Drug Project Research Group, 1975, Clofibrate and niacin in coronary heart disease, J. Amer. Med. Assoc. 231: 360–381.CrossRefGoogle Scholar
  21. Eisenberg, S., and Levy, R. I., 1975, Lipoprotein metabolism, in: Advances in Lipid Research, Vol. 13 ( R. Paoletti and D. Kritchevsky, eds.), pp. 1–89, Academic Press, New York.Google Scholar
  22. Eisenberg, S., Bilheimer, D. W., Levy, R. I., and Lindgren, F. T., 1973, On the metabolic conversion of human plasma very low density lipoprotein to low density lipoprotein, Biochim. Biophys. Acta 326: 361–377.PubMedGoogle Scholar
  23. Fogelman, A. M., Edmond, J., Seager, J., and Popjak, G., 1975, Abnormal induction of 3-hvdroxy-3-methylglutarvl coenzyme A reductase in leukocytes from subjects with heterozygous familial hypercholesterolemia, J. Biol. Chem. 250: 2045–2055.PubMedGoogle Scholar
  24. Fredrickson, D. S., 1975, Editorial: It’s time to be practical, Circulation 51: 20–9211.Google Scholar
  25. Fredrickson, D. S., Levy, R. I., and Lees, R. S., 1967, Fat transport in lipoproteins—An integrated approach to mechanisms and disorders, N. Engl. J. Med. 276: 34.PubMedCrossRefGoogle Scholar
  26. Fredrickson, D. S., Morganroth, J., and Levy, R. I., 1975, Type III hyperlipoproteinemia: An analysis of two contemporary definitions, Ann. Intern. Med. 82: 150–157.PubMedGoogle Scholar
  27. Glomset, J. A., and Norum, K. R., 1973, The metabolic role of lecithin:cholesterol acyltransferase: Perspectives from pathology, Adv. Lipid Res. 11: 1–65.Google Scholar
  28. Glomset, J. A., Norum, K. R., Nichols, A. V., King, W. C., Mitchell, C. D., Applegate, K. R., Gong, E. L., and Gjone, E., 1975, Plasma lipoproteins in familial lecithin:cholesterol acyltransferase deficiency: Effects of dietary manipulation, Scand J. Clin. Lab. Invest. 35 (Suppl. 142): 3–30.CrossRefGoogle Scholar
  29. Goldstein, J. L., and Brown, M. S., 1975, Hyperlipidemia in coronary heart disease: A biochemical genetic approach, J. Lab. Clin. Med. 85: 15–25.PubMedGoogle Scholar
  30. Goldstein, J. L., Hazzard, W. R., Bierman, E. L., Schrott, H. G., and Motulsky, A. G., 1973a, Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction, J. Clin. Invest. 52: 1533–1543.PubMedCrossRefGoogle Scholar
  31. Goldstein, J. L., Schrott, H. G., Hazzard, W. R., Bierman, E. L., and Motulsky, A. G., 1973b, Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia, J. Clin. Invest. 52: 1544–1568.PubMedCrossRefGoogle Scholar
  32. Goldstein, J. L., Brunschede, G. Y., and Brown, M. S., 1975a, Inhibition of the proteolytic degradation of low density lipoprotein in human fibroblasts by chloroquine, concanavalin A, and Triton WR 1339, J. Biol. Chem. 250: 7854–7862.PubMedGoogle Scholar
  33. Goldstein, J. L., Dana, S. E., Brunschede, G. Y., and Brown, M. S., 1975b, Genetic heterogeneity in familial hypercholesterolemia: Evidence for two different mutations affecting functions of low-density lipoprotein receptor, Proc. Nat. Acad. Sci. U.S.A. 72: 1092–1096.CrossRefGoogle Scholar
  34. Goldstein, J. L., Dana, S. E., Faust, J. R., Beaudet, A. L., and Brown, M. S., 1975c, Role of lysosomal acid lipase in the metabolism of plasma low density lipoprotein: Observations in cultured fibroblasts from a patient with cholesteryl ester storage disease, J. Biol. Chem. 250: 8487–8495.PubMedGoogle Scholar
  35. Hall, Y., Stamler, J., Cohen, D. B., Mojonnier, L., Epstein, M. B., Berkson, D. M., Whipple, I. T., and Catchings, S., 1972, Effectiveness of a low saturated fat, low cholesterol, weight-reducing diet for the control of hypertriglyceridemia, Atherosclerosis 16: 389–403.PubMedCrossRefGoogle Scholar
  36. Havel, R. J., 1975, Editorial: Hyperlipoproteinemia: Problems in diagnosis and challenges posed by the “type III” disorder, Ann. Intern. Med. 82: 273, 274.Google Scholar
  37. Hazzard, W. R., and Bierman, E. L., 1975a, Broad-ß disease versus endogenous hypertriglyceridemia: Levels and lipid composition of chylomicrons and very low density lipoproteins during fat-free feeding and alimentary lipemia, Metabolism 24: 817–828.PubMedCrossRefGoogle Scholar
  38. Hazzard, W. R., and Bierman, E. L., 1975b, The spectrum of electrophoretic mobility of very low density lipoproteins: Role of slower migrating species in endogenous hypertriglyceridemia (type IV hyperlipoproteinemia) and broad-ß disease (type III), I. Lab. Clin. Med. 86: 239–252.Google Scholar
  39. Hazzard, W. R., Goldstein, J. L., Schrott, H. G., Motulsky, A. G., and Bierman, E. L., 1973, Hyperlipidemia in coronary heart disease. III. Evaluation of lipoprotein phenotypes of 156 genetically defined survivors of myocardial infarction, J. Clin. Invest. 52: 1569–1577.PubMedCrossRefGoogle Scholar
  40. Hazzard, W. R., O’Donnell, T. F., and Lee, Y. L., 1975, Broad-ß disease (type III hyperlipoproteinemia) in a large kindred: Evidence for a monogenic mechanism, Ann. Intern. Med. 82: 141–149.PubMedGoogle Scholar
  41. Jackson, R. L., Sparrow, J. T., Baker, H. N., Morrisett, J. D., Taunton, O. D., and Gotto, A. M., Jr., 1974, The primary structure of apolipoprotein-serine, J. Biol. Chem. 249: 5308–5313.PubMedGoogle Scholar
  42. Kane, J. P., Sata, T., Hamilton, R. L., and Havel, R. J., 1975, Apoprotein composition of very low density lipoproteins of human serum, J. Clin. Invest. 56: 1622–1634.PubMedCrossRefGoogle Scholar
  43. Kannel, W. B., Dawber, T. R., Kagan, A., Revotskie, N., and Stokes, J., III, 1961, Factors of risk in the development of coronary heart disease—Six year follow-up experience. The Framingham study, Ann. Intern. Med. 55: 33–50.PubMedGoogle Scholar
  44. Kannel, W. B., Castelli, W. P., Gordon, T., and McNamara, P. M., 1971, Serum cholesterol, lipoproteins and the risk of coronary heart disease, Ann. Intern. Med. 74: 1–12.PubMedGoogle Scholar
  45. Kaufmann, R. L., Assal, J. Ph., Soeldner, J. S., Wilmshurst, E. G., Lemaire, J. R., Gleason, R. E., and White, P., 1975, Plasma lipid levels in diabetic children. Effect of diet restricted in cholesterol and saturated fats, Diabetes 24: 67 2679.Google Scholar
  46. Keys, A., 1975, Coronary heart disease—The global picture, Atherosclerosis 22: 149–192.PubMedCrossRefGoogle Scholar
  47. Khachadurian, A. K., Lipson, M., and Kawahara, F. S., 1975, Diagnosis of familial hypercholesterolemia by measurement of sterol synthesis in cultured skin fibroblasts, Atherosclerosis 21: 235–244.PubMedCrossRefGoogle Scholar
  48. Krogh, L., and Wickens, J. T., 1974, Portacaval shunt for hypercholesterolemia, S. Afr. Med. J. 48: (56): 2302.PubMedGoogle Scholar
  49. Lees, R. S., and Wilson, D. E., 1971, The treatment of hyperlipidemia, N. Engl. J. Med. 284: 186–195.PubMedCrossRefGoogle Scholar
  50. Levy, R. I., Morganroth, J., and Rifkind, B. M., 1974, Drug therapy. Treatment of hyperlipidemia, N. Engl. J. Med. 290: 1295–1301.PubMedCrossRefGoogle Scholar
  51. Lindner, A., Charra, B., Sherrard, D. J., and Scribner, B. H., 1974, Accelerated atherosclerosis in prolonged maintenance hemodialysis, N. Engl. J. Med. 290: 697–701.PubMedCrossRefGoogle Scholar
  52. Lux, S. E., John, K. M., Ronan, R., and Brewer, H. B., Jr., 1972, Isolation and characterization of the tryptic and cyanogen bromide peptides of ApoLy-Gln II (Apo-II), a plasma high density apolipoprotein, J. Biol. Chem. 247: 7519–7527.PubMedGoogle Scholar
  53. Mattson, F. H., Erickson, B. A., and Kligman, A. M., 1972, Effect of dietary cholesterol on serum cholesterol in man, Amer. J. Clin. Nutr. 25: 589–594.PubMedGoogle Scholar
  54. Mattson, F. H., Hollenbach, E. J., and Kligman, A. M., 1975, Effect of hydrogenated fat on the plasma cholesterol and triglyceride levels of man, Amer. J. Clin. Nutr. 28: 726–731.PubMedGoogle Scholar
  55. McCosh, E. J., Solangi, K., Rivers, J. M., and Goodman, A., 1975, Hypertriglyceridemia in patients with chronic renal insufficiency, Amer. J. Clin. Nutr. 28: 1036–1043.PubMedGoogle Scholar
  56. Mishkel, M. A., Nazir, D. J., and Crowther, S., 1975, A longitudinal assessment of lipid ratios in the diagnosis of type III hyperlipoproteinemia, Clin. Chim. Acta 58: 121–136.PubMedCrossRefGoogle Scholar
  57. Mitchell, S., and Levy, R. I., 1974, Portacaval shunt in familial hypercholesterolemia, Lancet 2: 1263–1264.PubMedCrossRefGoogle Scholar
  58. Morganroth, J:, Levy, R. I., and Fredrickson, D. S., 1975, The biochemical, clinical, and genetic features of type III hyperlipoproteinemia, Ann. Intern. Med. 82: 158–174.Google Scholar
  59. Morrisett, J. D., Jackson, R. L., and Gotto, A. M., Jr., 1975, Lipoproteins: Structure and function, Annu. Rev. Biochem. 44: 183–207.PubMedCrossRefGoogle Scholar
  60. Nikkilä, E. A., and Aro, A., 1973, Family study of serum lipids and lipoproteins in coronary heart disease, Lancet 1: 954–959.PubMedCrossRefGoogle Scholar
  61. Norum, K. R., Glomset, J. A., Nichols, A. V., Forte, T., Albers, J. J., King, W. C., Mitchell, C. D., Applegate, K. R., Gong, E. L., Cabana, V., and Gjone, E., 1975, Plasma lipoproteins in familial lecithin:cholesterol acyltransferase deficiency: Effects of incubation with lecithin:cholesterol acyltransferase in vitro, Scand. J. Clin. Lab. Invest. 35 (Suppl. 142): 31–55.CrossRefGoogle Scholar
  62. Patsch, J. R., Sailer, S., and Braunsteiner, H., 1975, Lipoprotein of the density 1.006–1.020 in the plasma of patients with type III hyperlipoproteinemia in the postabsorptive state, Eur. J. Clin. Invest. 5: 45–55.PubMedCrossRefGoogle Scholar
  63. Pierides, A. M., Alvarez-Ude, F., Kerr, D. N. S., and Skillen, A. W., 1975, Clofibrate-induced muscle damage in patients with chronic renal failure, Lancet 2: 1279–1282.PubMedCrossRefGoogle Scholar
  64. Rose, H. G., Kranz, P., Weinstock, M., Juliano, J., and Haft, J. I., 1973, Inheritance of combined hyperlipoproteinemia: Evidence for a new lipoprotein phenotype, Amer. J. Med. 54: 148–160.PubMedCrossRefGoogle Scholar
  65. Shulman, R. S., Herbert, P. N., Wehrly, K., and Fredrickson, D. S., 1975, The complete amino acid sequence of C-I (ApoLpSer), an apolipoprotein from human very low density lipoproteins, J. Biol. Chem. 250: 182–190.PubMedGoogle Scholar
  66. Sigler, G. F., Soutar, A., Gotto, A. M., Jr., and Sparrow, J. T., 1975, The total synthesis of apolipoprotein-C-I, Circulation 52 (Suppl. II): 11–17.Google Scholar
  67. Sigurdsson, G., Nicoll, A., and Lewis, B., 1975, Conversion of very low density lipoprotein to low density lipoprotein: A metabolic study of apolipoprotein B kinetics in human subjects, J. Clin. Invest. 56: 1481–1490.PubMedCrossRefGoogle Scholar
  68. Simons, L. A., Reichl, D., Myant, N. B., and Mancini, M., 1975, The metabolism of the apoprotein of plasma low density lipoprotein in familial hyperbetalipoproteinemia in the homozygous form, Atherosclerosis 21: 283–298.PubMedCrossRefGoogle Scholar
  69. Slack, J., 1969, Risks of ischemic heart disease in familial hyperlipoproteinemia states, Lancet 2: 1380–1382.PubMedCrossRefGoogle Scholar
  70. Starzl, T. E., Putnam, C. W., Chase, H. P., and Porter, K. A., 1973, Portacaval shunt in hyperlipoproteinemia, Lancet 2: 940–944.PubMedCrossRefGoogle Scholar
  71. Starzl, T. E., Chase, H. P., Putnam, C. W., Nora, J. J., Fennell, R. H., Jr., and Porter, K. A., 1974, Portacaval shunt in hyperlipidemia, Lancet 2: 1263.PubMedCrossRefGoogle Scholar
  72. Stein, E. A., Mieny, C., Spitz, L., Saaron, I., Pettifor, J., Heimann, K. W., Bersohn, I., and Dinner, M., 1975, Portacaval shunt in four patients with homozygous hypercholesterolemia, Lancet 1: 832–835.PubMedCrossRefGoogle Scholar
  73. Stone, N. J., Levy, R. I.,.Fredrickson, D. S., and Verter, J., 1974, Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia, Circulation 49: 476–488.Google Scholar
  74. Teisberg, P., Gjone, E., and Olaisen, B., 1975, Genetics of LCAT (lecithin:cholesterol acyltransferase) deficiency, Ann. Hum. Genet. London 38: 327–331.CrossRefGoogle Scholar
  75. Thompson, G. R., Lowenthal, R., and Myant, N. B., 1975, Plasma exchange in the management of homozygous familial hypercholesterolemia, Lancet 1: 1208–1211.PubMedCrossRefGoogle Scholar
  76. Torsvik, H., Fischer, J. E., Feldman, H. A., and Lees, R. S., 1975, Effects of intravenous hyperalimentation on plasma-lipoproteins in severe familial hypercholesterolemia, Lancet 1: 601–604.PubMedCrossRefGoogle Scholar
  77. Wilson, W. S., Hulley, S. B., Burrows, M. I., and Nichaman, M. Z., 1971, Serial lipid and lipoprotein responses to the American Heart Association fat-controlled diet, Amer. J. Med. 51: 491–503.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1976

Authors and Affiliations

  • DeWitt S. Goodman
    • 1
  1. 1.Department of MedicineCollege of Physicians and Surgeons of Columbia UniversityNew YorkUSA

Personalised recommendations